Loxo Oncology to Present Preclinical Data for LOXO-292 and LOXO-195 at the 28th EORTC-NCI-AACR Symposium
November 15 2016 - 06:45AM
Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company
innovating the development of highly selective medicines for
patients with genetically defined cancers, today announced that new
preclinical data for the company’s LOXO-292 and LOXO-195 programs
will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer Therapeutics taking place November 29 – December
2, 2016 in Munich, Germany.
The details of the poster presentations are as follows:
LOXO-292
Date: December 1, 2016Title:
The development of a potent, KDR/VEGFR2-sparing RET kinase
inhibitor for treating patients with RET-dependent
cancersSession: Molecular targeted agents
IIAbstract Code:
441Poster Number:
120Location: Exhibition Hall
LOXO-195
Date: December 1, 2016Title:
The development of LOXO-195, a second generation TRK kinase
inhibitor that overcomes acquired resistance to 1st generation
inhibitors observed in patients with TRK-fusion
cancersSession: Molecular targeted agents
IIAbstract Code:
442Poster Number:
121Location: Exhibition Hall
About Loxo OncologyLoxo Oncology is a
biopharmaceutical company innovating the development of highly
selective medicines for patients with genetically defined cancers.
Our pipeline focuses on cancers that are uniquely dependent on
single gene abnormalities, such that a single drug has the
potential to treat the cancer with dramatic effect. We believe that
the most selective, purpose-built medicines have the highest
probability of maximally inhibiting the intended target, thereby
delivering best-in-class disease control and safety. Our management
team seeks out experienced industry partners, world-class
scientific advisors and innovative clinical-regulatory approaches
to deliver new cancer therapies to patients as quickly and
efficiently as possible. For more information, please visit the
company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:Jacob S. Van NaardenChief Business
Officerjake@loxooncology.com
Investors:Peter RahmerThe Trout Group,
LLC646-378-2973prahmer@troutgroup.com
Media:Dan BudwickPure Communications,
Inc.973-271-6085dan@purecommunicationsinc.com
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Feb 2024 to Mar 2024
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Mar 2023 to Mar 2024